Denali Therapeutics DNLI 深 沪
等待开盘 12-05 09:30:00 美东时间
20.11
+1.110
+5.84%
华盛通- 最 高20.485
- 今 开18.77
- 成交量 253.70万股
- 最 低 18.47
- 昨 收 19.00
- 总市值 29.56亿
- 52周最高 24.345
- 市盈率 静 --
- 换手率 1.73%
- 52周最低 10.57
- 委 比 27.16%
- 总股本 1.47亿
- 历史最高 93.94
- 量 比 2.01
- 振 幅 10.61%
- 历史最低 10.57
- 每 手 1
- 风险率 3.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Denali Therapeutics And Royalty Pharma Announce $275M Synthetic Royalty Funding Agreement Based On Future Net Sales Of Tividenofusp Alfa
Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.Tividenofusp alfa is Denali's
12-04 20:05
Catalyst Watch: Holiday shopping data, Amazon event, and Salesforce earnings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - December ...
11-29 02:30
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
JP Morgan Maintains Overweight on Denali Therapeutics, Raises Price Target to $26
JP Morgan analyst Jessica Fye maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $24 to $26.
11-04 23:00
Denali Therapeutics Faces FDA Review Extension
Denali Therapeutics ( ($DNLI) ) has shared an update. On October 13, 2025, Dena...
10-14 20:28
Denali Therapeutics Announces FDA Extends The Review Timeline For Its Biologics License Application For Tividenofusp Alfa, A Potential Treatment For Hunter Syndrome
Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated approval of
10-14 04:03
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
Cantor Fitzgerald Reiterates Overweight on Denali Therapeuticsto Overweight
Cantor Fitzgerald analyst Josh Schimmer reiterates Denali Therapeutics (NASDAQ:DNLI) from Overweight to Overweight.
09-08 21:20
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
Denali's Form S-4 registration statement has been approved by the SEC, enabling the proposed business combination with Semnur. The extraordinary general meeting of Denali shareholders to vote on this transaction is scheduled for September 3, 2025. Upon completion, the combined entity will operate as Semnur Pharmaceuticals, Inc. Scilex Holding Company, the parent of Semnur, specializes in non-opioid pain management solutions and has a diverse port...
08-13 10:00
Denali Therapeutics Advances in Neurodegenerative Treatments
Denali Therapeutics ( ($DNLI) ) has released its Q2 earnings. Here is a breakdo...
08-12 14:50
